A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102 for n Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
• Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements.
• The age of signing the informed consent is \>= 18 years, regardless of gender.
• Subject with advanced or distant metastatic squamous cell carcinoma of the head and neck confirmed by histology or cytology.
• Tumors with primary foci located in the oropharynx, oral cavity, hypopharynx and larynx.
• Provide archived or fresh tumor tissue for test.
• At least one measurable lesion according to RECIST v1.1 criteria.
• The ECOG score is 0 or 1.
• Expected survival ≥12 weeks.
• Good level of organ function.
⁃ Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.